These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9814878)

  • 1. Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care.
    Dickinson BP; Mitty JA; Mylonakis E; Rich JD; Merriman NA; Tashima KT; Carpenter CC; Flanigan TP
    AIDS; 1998 Oct; 12(15):2075-6. PubMed ID: 9814878
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.
    Ekouévi DK; Avettand-Fènoël V; Tchounga BK; Coffie PA; Sawadogo A; Minta D; Minga A; Eholie SP; Plantier JC; Damond F; Dabis F; Rouzioux C;
    PLoS One; 2015; 10(6):e0129886. PubMed ID: 26111242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in plasma HIV-RNA and CD4 lymphocyte counts in patients receiving highly active antiretroviral therapy.
    Maggiolo F; Bottura P; Capra R; Pirali A; Zaffaroni P; Suter F
    AIDS; 1999 Aug; 13(12):1594-5. PubMed ID: 10465093
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial design in the era of highly effective antiviral drug combinations for HIV infection.
    DeGruttola V; Hughes M; Gilbert P; Phillips A
    AIDS; 1998; 12 Suppl A():S149-56. PubMed ID: 9632997
    [No Abstract]   [Full Text] [Related]  

  • 7. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
    Chirwa LI; Johnson JA; Niska RW; Segolodi TM; Henderson FL; Rose CE; Li JF; Thigpen MC; Matlhaba O; Paxton LA; Brooks JT
    AIDS; 2014 Jan; 28(2):223-6. PubMed ID: 24361682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy.
    Shoko C; Chikobvu D
    BMC Infect Dis; 2019 Feb; 19(1):169. PubMed ID: 30770728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral rounds. CD4 count 423, viral load 12,000: time to treat anyway?
    Hodder S; Frank I
    AIDS Clin Care; 2006 Jun; 18(6):59-60. PubMed ID: 16791955
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the principles of anti-HIV drug therapy.
    Horn T
    Surviv News (Atlanta Ga); 2001 Jul; ():13. PubMed ID: 11683014
    [No Abstract]   [Full Text] [Related]  

  • 12. [HIV viral load and preventive HIV load in primary health care].
    Vall Mayans M
    Aten Primaria; 1997 Nov; 20(8):399-400. PubMed ID: 9462932
    [No Abstract]   [Full Text] [Related]  

  • 13. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
    Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
    J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 16. [Viral load and CD4+ lymphocyte count in the era of highly active antiretroviral therapy].
    Martín JC; Fernández P; Soriano V; Martínez P; González-Lahoz J
    Med Clin (Barc); 2000 Jun; 115(3):118. PubMed ID: 10965488
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV agents. How long will a first regimen last?
    TreatmentUpdate; 2003; 15(5):1-2. PubMed ID: 17219614
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case of the undetectable viral load.
    Jenny-Avital ER
    AIDS Clin Care; 1999 Mar; 11(3):20-1. PubMed ID: 11366207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study.
    Petoumenos K; Watson J; Whittaker B; Hoy J; Smith D; Bastian L; Finlayson R; Sloane A; Wright ST; McManus H; Law MG
    J Int AIDS Soc; 2015; 18(1):19392. PubMed ID: 25680919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.